{
	"formData": {
		"accrualType": "病人",
		"sponsorAddress": "陽明大學守仁樓316",
		"genderEnum": "女",
		"croAddress": "croAddresscroAddress",
		"accrualTaiwan": "30",
		"title": "對晚期實體腫瘤患者進行的HLX10 (作用於人類凋亡蛋白第一型之單株抗體)第一期人體劑量遞增性研究",
		"衛福部核准日期": "2018-09-20",
		"locations": [
			"門診處",
			"病房"
		],
		"sponsorName": "漢霖生技股份有限公司",
		"insuranceInst": "台灣人壽",
		"crcNum": "crcNum",
		"2-1.IRB核准日期": "2018-09-20",
		"croName": "百瑞精鼎國際股份有限公司",
		"LAIs": [],
		"AIs": [
			{
				"title": "主治醫師",
				"name": "劉偉修",
				"branch": "其他",
				"email1": "au3232323232@mail.ndmctsgh.edu.tw"
			}
		],
		"accrualGlobal": "30",
		"proposedStartDate": "2018-06-08",
		"accrualHospital": "10",
		"protocolVersion": "Oscar test version Update",
		"funds": [
			"廠商"
		],
		"preview": {
			"emailPI": "AU674676463@mail.ndmctsgh.edu.tw",
			"piAccountFlg": true,
			"titlePI": "主治醫師",
			"branchPI": "其他",
			"lastNamePI": "王甯祺"
		},
		"PI": [
			{
				"title": "主治醫師",
				"name": "王甯祺",
				"branch": "其他",
				"email1": "AU674676463@mail.ndmctsgh.edu.tw"
			}
		],
		"nihReason": "測試案件nihReason",
		"insuranceAmount": "200萬",
		"dohApprovedNum": "",
		"irbNum": "2-106-01-024",
		"engTitle": "A PHASE 1 STUDY OF HLX10, A HUMANIZED MONOCLONAL ANTIBODY TARGETING PROGRAMMED DEATH-1 (PD-1) PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMORS",
		"contractFlg": "否",
		"proposedEndDate": "2018-06-08"
	}
}